Development of adjuvants for CTL induction using high active form of lymphotactin/XCL1
| Project/Area Number |
26860775
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | ケモカイン / ワクチン / アジュバント / CTL / ワクチンアジュバント |
|---|
| Outline of Final Research Achievements |
Recent studies have indicated that targeting antigens to XCR1, a chemokine receptor selectively expressed on cross-presenting dendritic cells using antigen fused to XCL1/Lymphotactin, an XCR1 ligand, represents an effective induction of CD8+ T cell response. In this study, we generate a high active form of XCL1 (XCL1-CC3) and investigate in vivo adjuvant efficacy. Wild-type XCL1 (XCL1-WT) have higher cell migration activity and calcium mobilization activity than XCL1-CC3. When intradermally injected with ovalbumin as a model antigen, both XCL1-WT and XCL1-CC3 induced potent CD8+ T cell responses and XCL1-CC3 showed more effective CD8+ T cell-mediated antitumor immunity than XCL1-WT. In addition, XCL1-CC3 enhanced an accumulation of CD103+XCR1+ cross-presenting dendritic cells rather than XCL1-WT. The present results indicate that XCL1-CC3 has potential to induce more efficient CD8+ T cells responses as CTL-inducing vaccine adjuvant than XCL1-WT.
|
Report
(4 results)
Research Products
(9 results)
-
[Journal Article] Efficient use of a crude drug/herb library reveals Ephedra Herb as a specific antagonist for Th2-specific chemokine receptors CCR3, CCR4, and CCR82016
Author(s)
Matsuo K, Koizumi K, Fujita M, Morikawa T, Jo M, Shibahara N, Saiki I, Yoshie O, Nakayama T
-
Journal Title
Front. Cell Dev. Biol.
Volume: 4
Pages: 54-54
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
